Annan Liu
Overview
Explore the profile of Annan Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen F, Wan S, Hao J, Sun K, Liu A, Zhu L, et al.
Chronic Dis Transl Med
. 2025 Mar;
11(1):69-77.
PMID: 40051824
Background: The prevalence of type 2 diabetes mellitus (T2DM) has been rapidly growing in Chinese populations in recent decades, and the shift in eating habits is a key contributing factor...
2.
Nanozyme as tumor energy homeostasis disruptor mediated ferroptosis for high-efficiency radiotherapy
Li X, Zhang Y, Liu A, Li L, Yang X, Wang Y, et al.
J Colloid Interface Sci
. 2025 Feb;
688:44-58.
PMID: 39987840
Radioresistance in tumors, driven by the insufficiency and rapid depletion of reactive oxygen species (ROS), limits the efficacy of radiotherapy (RT). This study introduces an Ir@Au nanozyme that enhances tumor...
3.
Liu A, Li L, Wang Z, Li X, Liang H, Yang J, et al.
Anal Chem
. 2025 Jan;
97(4):2232-2243.
PMID: 39825800
As the most common and lethal cancer of the female gonads, ovarian cancer (OC) has a grave impact on people's health. OC is asymptomatic, insidious in onset, difficult to diagnose...
4.
Wang Z, Feng Y, Xing H, Guo W, Liu A, Liang H, et al.
J Colloid Interface Sci
. 2024 Dec;
683(Pt 1):994-1007.
PMID: 39719806
Triple-negative breast cancer (TNBC) with highly malignant and aggressive, still faces challenges in treatment due to the single treatment and side effects. It is urgent to develop an advanced theranostic...
5.
Li X, Zhang X, Song L, Li Y, Liu A, Li L, et al.
ACS Nano
. 2024 Dec;
18(51):34656-34670.
PMID: 39661982
Breaking the balance of the tumor microenvironment and reshaping it sustainably remain major challenges in lung cancer treatment. Here, a "tumor energy homeostasis disruptor", the CuO@Au nanozyme was developed, which...
6.
Li X, Hao M, Liu A, Li L, Nesic M, Yang B, et al.
Acta Biomater
. 2024 Oct;
190:476-487.
PMID: 39401597
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the head and neck region, and its treatment is limited by hypoxia and inadequate oxygen supply. Continuous oxygen...
7.
Wang Z, Sha T, Li J, Luo H, Liu A, Liang H, et al.
Bioact Mater
. 2024 Jun;
39:612-629.
PMID: 38883315
As a "cold tumor", triple-negative breast cancer (TNBC) exhibits limited responsiveness to current immunotherapy. How to enhance the immunogenicity and reverse the immunosuppressive microenvironment of TNBC remain a formidable challenge....
8.
Tang X, Eid A, Zhang R, Cheng Y, Liu A, Chen Y, et al.
Plant Genome
. 2024 May;
17(2):e20465.
PMID: 38807445
The clustered regularly interspaced short palindromic repeats (CRISPR) systems have been demonstrated to be the foremost compelling genetic tools for manipulating prokaryotic and eukaryotic genomes. Despite the robustness and versatility...
9.
Wang Z, Shen Z, Liu A, Liang H, Li X, Guan L, et al.
ACS Appl Mater Interfaces
. 2024 Apr;
16(15):18551-18563.
PMID: 38564314
High levels of reactive oxygen species (ROS) are known to play a critical role in the secondary cascade of spinal cord injury (SCI). The scavenging of ROS has emerged as...
10.
Wang Z, Ren X, Li Y, Qiu L, Wang D, Liu A, et al.
ACS Nano
. 2024 Apr;
18(14):10288-10301.
PMID: 38556985
Insufficient reactive oxygen species (ROS) production and radioresistance have consistently contributed to the failure of radiotherapy (RT). The development of a biomaterial capable of activating ROS-induced apoptosis and ferroptosis is...